Literature DB >> 3168209

Non-resolving jaundice: bilirubin covalently attached to serum albumin circulates with the same metabolic half-life as albumin.

R G Reed1, L K Davidson, C M Burrington, T Peters.   

Abstract

In hepatobiliary disease and biliary obstruction, bilirubin often becomes covalently bound to albumin circulating in serum, producing a nondissociable complex. To determine how long this complexed bilirubin remains in the circulation, we compared the metabolic clearance of bilirubin-albumin complexes with the clearances of free bilirubin and unmodified albumin. Radiolabeled bilirubin, albumin, and covalent bilirubin-albumin were injected into the circulation of Sprague-Dawley rats and serial samples of plasma were analyzed for the injected compounds. The half-life of bilirubin was 6.2 min. The half-life of bilirubin covalently bound to rat serum albumin was 1.9 to 2.1 days, identical to that of unmodified rat albumin. We conclude that bilirubin covalently attached to albumin is maintained in the circulation with the long half-life of albumin rather than the short half-life of bilirubin. Because albumin in humans has a half-life of 19 days, covalent attachment of bilirubin to human albumin could result in persistence of hyperbilirubinemia long after the resolution of disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3168209

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  4 in total

1.  Bile acid profile and decrement rate of serum total bilirubin after biliary drainage.

Authors:  T Kosuge; T Beppu; S Iwasaki; T Itoh; Y Idezuki
Journal:  Gastroenterol Jpn       Date:  1990-12

2.  Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein.

Authors:  Jian Meng; Xiao-Yun Liu; Sheng Ma; Hua Zhang; Song-da Yu; Yi-Fan Zhang; Mei-Xia Chen; Xiao-Yu Zhu; Yi Liu; Ling Yi; Xiao-Liang Ding; Xiao-Yan Chen; Li-Yan Miao; Da-Fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-10-31       Impact factor: 6.150

3.  Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether-lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso.

Authors:  Yves Daniel Compaoré; Issaka Zongo; Anyirékun F Somé; Nouhoun Barry; Frederick Nikiéma; Talato N Kaboré; Aminata Ouattara; Zachari Kabré; Kadidiatou Wermi; Moussa Zongo; Rakiswende S Yerbanga; Issaka Sagara; Abdoulaye Djimdé; Jean Bosco Ouédraogo
Journal:  Malar J       Date:  2021-01-29       Impact factor: 2.979

4.  Marked increase in rat red blood cell membrane protein glycosylation by one-month treatment with a cafeteria diet.

Authors:  Laia Oliva; Cristian Baron; José-Antonio Fernández-López; Xavier Remesar; Marià Alemany
Journal:  PeerJ       Date:  2015-07-16       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.